

ASX RELEASE

30 January 2020

**Section 708A Notice – Allotment of 13,292,600 Shares**

Amplia Therapeutics Limited (“ATX” or “the Company”) completed an allotment of 13,292,600 ordinary fully paid shares at the issue price of \$0.07 per share on 24 January 2020 to raise gross proceeds of \$930,482 to complete the clinic-enabling studies that were initiated during 2019 and for working capital purposes.

All of the shares issued will rank pari passu with existing ATX ordinary shares.

In accordance with Section 708A (5)(e) of the Act, the Company gives notice that:

- The Company has issued these shares without disclosure to investors under Part 6D.2 of the Act;
- As at the date of this notice, the Company has complied with:
  - the provisions of Chapter 2M of the Act as they apply to the Company;
  - Section 674 of the Act
- As at the date of this notice there is no excluded information (as defined in Sections 708A (7) and 708A(8) of the Act) which is required to be disclosed by the Company under Section 708(6) of the Act.

- End -

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics Limited.

**For Further Information**

Andrew J. Cooke  
Director and Company Secretary  
[andrew@ampliatx.com](mailto:andrew@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)